AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Aminoacyl tRNA synthase complex-interacting multifunctional protein 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q12904

UPID:

AIMP1_HUMAN

Alternative names:

Multisynthase complex auxiliary component p43

Alternative UPACC:

Q12904; B3KTR2; B4E1S7; Q6FG28; Q96CQ9

Background:

Aminoacyl tRNA synthase complex-interacting multifunctional protein 1, also known as the multisynthase complex auxiliary component p43, plays a pivotal role in protein synthesis and various cellular processes. It is involved in the stimulation of cytoplasmic arginyl-tRNA synthase activity, tRNA binding, and possesses inflammatory cytokine activity. Additionally, it has a significant role in glucose homeostasis, wound repair, angiogenesis, and the modulation of endothelial cell responses.

Therapeutic significance:

The protein's involvement in hypomyelinating leukodystrophy, a severe neurological disorder, underscores its therapeutic potential. Understanding the role of Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 could open doors to potential therapeutic strategies for treating this debilitating condition.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.